Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 6/20 | 0.32 |
| ▸ | BCHE | P06276 | 5/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22021900 | 0.90 | EPHX2 (0.36) | EPHX2ACHEBCHE | |
| SCHEMBL22166526 | 0.86 | EPHX2 (0.40) | EPHX2ACHEBCHE | |
| SCHEMBL22021659 | 0.84 | EPHX2 (0.39) | EPHX2ACHEBCHE | |
| SCHEMBL22021680 | 0.83 | EPHX2 (0.41) | EPHX2ACHEBCHE | |
| SCHEMBL22021685 | 0.83 | EPHX2 (0.41) | EPHX2ACHEBCHE | |
| SCHEMBL22021658 | 0.83 | EPHX2 (0.41) | EPHX2ACHEBCHE | |
| SCHEMBL22166531 | 0.77 | EPHX2 (0.53) | EPHX2 | |
| SCHEMBL22166535 | 0.77 | EPHX2 (0.53) | EPHX2 | |
| SCHEMBL22021679 | 0.76 | EPHX2 (0.36) | EPHX2ACHEBCHE | |
| SCHEMBL22021691 | 0.75 | EPHX2 (0.50) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11642342-B2 | Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer | Accutar Biotechnology (US) | 2023-05-09 | — | — | US | disclosed |
| US-20210213012-A1 | COMBINATIONS OF ESTROGEN RECEPTOR DEGRADERS AND CYCLIN-DEPENDENT KINASE INHIBITORS FOR TREATING CANCER | ACCUTAR BIOTECHNOLOGY INC. | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210213012-A1 | COMBINATIONS OF ESTROGEN RECEPTOR DEGRADERS AND CYCLIN-DEPENDENT KINASE INHIBITORS FOR TREATING CANCER | CDK3, CDK4, CDK1 | EPHX2 1763/4885ACHE 4235/4885BCHE 3024/4885 |
| US-11642342-B2 | Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer | CDK3, CDK4, CDK1 | EPHX2 1763/4885ACHE 4235/4885BCHE 3024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.